BMRN vs VRTX: How BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases and Vertex Pharmaceuticals Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BMRN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMRN and VRTX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMRN and VRTX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases, a niche where it has decades of experience. Its commercial base includes enzyme replacement therapies (Vimizim, Naglazyme, Palynziq and others) for lysosomal and metabolic disorders, plus Voxzogo, an injectable for children with achondroplasia that has become the company's fastest-growing product. In April 2026 BioMarin closed its roughly $4.8 billion all-cash acquisition of Amicus Therapeutics, adding Galafold for Fabry disease and the Pombiliti plus Opfolda regimen for Pompe disease to the portfolio. Separately, the company decided to withdraw its Roctavian hemophilia gene therapy from the market after failing to find a buyer, taking an asset write-down.

Full BMRN guide

Vertex Pharmaceuticals is a Boston-based biotechnology company that designs medicines targeting the root molecular cause of serious diseases rather than only their symptoms. Its foundation is cystic fibrosis (CF), a genetic disease in which a defective CFTR protein disrupts salt and water movement in cells, damaging the lungs and other organs. Vertex developed the first drugs that correct the underlying protein defect, progressing from Kalydeco to Orkambi and Symdeko and then to the breakthrough triple-combination Trikafta (marketed as Kaftrio in Europe), which treats the large majority of CF patients. In late 2024 it began rolling out Alyftrek, a next-generation once-daily successor designed to extend that franchise and its patent protection. Because CF is a rare disease with essentially no competing root-cause therapy, Vertex has enjoyed pricing power and durable, high-margin revenue.

Full VRTX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BMRN drivers: Voxzogo growth engine; Amicus acquisition and portfolio breadth.
• VRTX drivers: A durable, high-margin cystic fibrosis near-monopoly; Journavx opens a large non-opioid pain market.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. For VRTX, the central risk is revenue concentration: cystic fibrosis still accounts for the overwhelming majority of Vertex's sales, so any disruption, whether a safety signal, a competing modulator, or pricing pressure, would hit the core disproportionately, and the newer products remain small by comparison.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BMRN if you believe its drivers more; VRTX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMRN and VRTX guides.

BMRN. BioMarin posted record 2025 revenue of about $3.2 billion and raised its 2026 revenue guidance to roughly $3.83 to $3.93 billion after adding the Amicus products, implying around 20 percent growth at the midpoint. Non-GAAP EPS guidance for 2026 was trimmed slightly to about $4.85 to $5.05 to reflect near-term dilution from the acquisition. Reported trailing GAAP multiples look elevated versus biotech peers, so the story depends on the guided growth materializing.

VRTX. Vertex trades at a premium to the large-cap pharma average, with a trailing P/E near the high 20s and a forward P/E around 25, reflecting both its high margins and near-monopoly economics in cystic fibrosis and the market's expectation that the pain, cell-therapy, and pipeline programs will add a second and third growth engine. Because the CF franchise is so profitable and the balance sheet holds substantial net cash, much of the valuation debate is about how much credit to give unproven pipeline assets. Vertex does not pay a dividend, so returns depend entirely on earnings growth and multiple, which makes clinical and launch execution the key swing factors.

Headline figures (approximate, JULY 2026): BMRN shows revenue (2025) ~$3.2B, 2026 revenue guidance ~$3.83B to $3.93B, q1 2026 revenue ~$766M, q1 2026 non-gaap eps ~$0.76; VRTX shows revenue (fy 2025) ~$12.0 billion, revenue growth (fy 2025) ~9%, revenue guidance (fy 2026) ~$12.95 billion to $13.1 billion, trailing p/e (approx.) ~29x.

BMRN and VRTX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BMRN and VRTX exposure against your real portfolio. It is not an investment adviser.